Docetaxel in the treatment of breast cancer: Current experience and future prospects

Expert Review of Anticancer Therapy

Volumn 5, Issue 4, 2005, Pages 613-633

  Nabholtz, Jean Marc ^a   Gligorov, Joseph ^b  

^a Breast Cancer Research Institute   (France)

^b HÔPITAL TENON   (France)

Author keywords

Adjuvant; Breast cancer; Chemotherapy; Combination therapy; Docetaxel; Monotherapy; Neoadjuvant; Taxane; Tolerability

Indexed keywords

ANTHRACYCLINE; BETA INTERFERON; CAPECITABINE; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EDATREXATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; MIDAZOLAM; NAVELBINE; PACLITAXEL; PLASMA PROTEIN; POLYAMINE DERIVATIVE; PREDNISONE; PROTEIN BCL 2; TAMOXIFEN; TAXANE DERIVATIVE; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VINCRISTINE;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; BLOOD TOXICITY; BODY WEIGHT DISORDER; BREAST CANCER; CANCER INHIBITION; CANCER MORTALITY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EARLY CANCER; EDEMA; FATIGUE; FLUID RETENTION; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HORMONAL THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION; METASTASIS; MICROTUBULE ASSEMBLY; MYALGIA; NAIL DISEASE; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; POLYMERIZATION; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMATITIS; TREATMENT FAILURE; TREATMENT OUTCOME; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; TAXOIDS;

EID: 24044477528     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.5.4.613     Document Type: Review

References (141)

1. Greenlee RT, Hill-Harmon MB, Murray Y, Thun M. Cancer Statistics, 2001. CA Cancer J. Clin. 51(1), 15-36 (2001).
2. Hankey B, Brinton L, Kessler L, Abrams J. Section IV: breast. In: SEER Cancer Statistics Review 1973-1990. Miller B, Ries L, Hankey B et al. (Eds). US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, DHHS publication no. (NIH)93-2789, Bethesda, MD, USA (1993).
3. Hill C, Doyon F. Cancer prevalence in France. Bull Cancer 88(10), 1019-1022 (2001).
4. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352(9132), 930-942 (1998).
5. Perez EA. Current management of metastatic breast cancer. Semin. Oncol. 26(Suppl. 12), 1-10 (1999).
6. Nabholtz JM, Tonkin K, Smylie M, Au HJ, Lindsay MA, Mackey J. Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer? Exp. Opin. Pharmacother. 1(2), 187-206 (2000).
7. Singletary SE, Allred C, Ashley P et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J. Clin. Oncol. 20(17), 3628-3636 (2002).
8. The National Institutes of Health Consensus Development Conference. Adjuvant Therapy for Breast Cancer. Bethesda, Maryland, USA. November 1-3, 2000. Proceedings. J. Natl. Cancer Inst. Monogr. 30, 1-152 (2001).
9. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J. Clin. Oncol. 21(17), 3357-3365 (2003).
10. Kaufmann M, von Minckwitz G, Smith R et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J. Clin. Oncol. 21(13), 2600-2608 (2003).
11. Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, PA, USA. Cancer 100(12), 2512-2532 (2004).
12. Fossati R, Confolonieri C, Torri V et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J. Clin. Oncol. 16, 3439-3460 (1998).
13. Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N. Engl. J. Med. 332(14), 901-906 (1995).
14. Aapro M. Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings. Semin. Oncol. 26(1 Suppl. 3), 17-21 (1999).
15. Fornier M, Munster P, Seidman AD. Update on the management of advanced breast cancer. Oncology 13(5), 647-658 (1999).
16. Crown J. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer. Semin. Oncol. 26(1 Suppl. 3), 5-9 (1999).
17. Nabholtz JM. The role of taxanes in the management of breast cancer. Semin. Oncol. 26(3 Suppl. 8), 1-3 (1999).
18. Nabholtz JM, Reese DM, Lindsay MA, Riva A. Combination chemotherapy for metastatic breast cancer. Expert Rev. Anticancer Ther. 2, 169-180 (2002).
19. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N. Engl. J. Med. 344(11), 783-92 (2001).
20. Extra JM, Cognetti F, Chan S et al. Randomized Phase II trial (M77001) of trastuzumab (Trastuzumab) plus docetaxel versus docetaxel alone, as first line therapy in patients with Her-2 positive metastatic breast cancer. Eur. J. Cancer 1, 672a. (2003).
21. Pegram MD, Pienkowski T, Northfelt DW et al. Results of two open-label, multicenter Phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J. Natl. Cancer Inst. 96(10), 759-769 (2004).
22. Esteva FJ. The current status of docetaxel for metastatic breast cancer. Oncology 16(6 Suppl. 6), 17-26 (2002).
23. Holmes FA, Walters RS, Theriault RL et al. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst. 83(24), 1797-1805 (1991).
24. Nabholtz JM, Gelmon K, Bontenbal M et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J. Clin Oncol. 14(6), 1858-1867 (1996).
25. Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9(Suppl. 2), 3-8 (2004).
26. Hennequin C, Giocanti N, Favaudon V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br. J. Cancer 71(6), 1194-1198 (1995).
27. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 17(3), 1061-1070 (1999).
28. Schimming R, Mason KA, Hunter N et al. Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chemother. Pharmacol. 43(2), 165-172 (1999).
29. Berchem GJ, Bosseler M, Mine N et al. Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2. Anticancer Res. 19(1A), 535-540 (1999).
30. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res. 57(2), 229-233 (1997).
31. Kraus LA, Schmid SM, Coffield RT et al. The mechanism of action of docetaxel and paclitaxel in xenograft models is not limited to Bcl-2 phosphorylation. Proc. Am. Assoc. Cancer Res. 40, 578 (1999).
32. Barendsz-Janson AF, Toebes EAH, Hillen HFP et al. Anti-angiogenic effect of tumor-drugs. Ann. Oncol. 9(Suppl. 2), 78 (1998).
33. Hortobagyi GN. Recent progress in the clinical development of docetaxel (Taxotere). Semin. Oncol. 26(Suppl. 9), 32-36 (1999).
34. Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, Sparaino JA, Schwartz EL. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol. Cancer Ther. 1(13), 1191-1200 (2000).
35. Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L. Docetaxel enhances tumor radioresponse in vivo. Clin. Cancer Res. 3(12 Pt 1), 2431-2438 (1997).
36. Mason KA, Kishi K, Hunter N et al. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin. Cancer Res. 5(12), 4191-4198 (1999).
37. Figgitt DP, Wiseman LR. Docetaxel: an update of its use in advanced breast cancer. Drugs 59(3), 621-651 (2000).
38. Taxotere® (docetaxel) for Injection Concentrate. Aventis Pharmaceuticals, New Jersey, IN, USA (2002).
39. Urien S, Barré J, Morin C et al. Docetaxel serum protein binding with high affinity to alpha-1-acid glycoprotein. Invest. New Drugs 14(2), 147-151 (1996).
40. Goh BC, Lee SC, Wang LZ et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J. Clin. Oncol. 20(17), 3683-3690 (2002).
41. Van Den Neste E, de Valeriola D, Kerger J et al. A Phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. Clin. Cancer Res. 6(1), 64-71 (2000).
42. Campone M, Fumoleau P, Delecroix V et al. Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. Ann. Oncol. 12(7), 909-918 (2001).
43. Schrijvers D, Pronk L, Highley M et al. Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a Phase I pharmacologic study. Am. J. Clin. Oncol. 23(4), 358-363 (2000).
44. Esposito M, Venturini M, Vannozzi MO et al. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. J. Clin. Oncol. 17(4), 1132-1140 (1999).
45. Lunardi G, Venturini M, Vannozzi MO et al. Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer. Ann. Oncol. 13(2), 280-285 (2002).
46. Ardiet CJ, Tranchand B, Zanetta S et al. A sensitive docetaxel assay in plasma by solid-phase extraction and high performance liquid chromatography-UV detection: validation and suitability in Phase I clinical trial pharmacokinetics. Invest. New Drugs. 17(4), 325-333 (1999).
47. D'Incalci M, Schuller J, Colombo T, Zucchetti M, Riva A. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations. Semin Oncol. 25(6 Suppl. 13), 16-20 (1998).
48. Gianni L, Vigano L, Locatelli A et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J. Clin. Oncol. 15(5), 1906-1915 (1997).
49. Ten Tije AJ, Verweij J, Carducci MA et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J. Clin. Oncol. 23(6), 1070-1077 (2005).
50. Fulton B, Spencer CM. Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 51(6), 1075-1092 (1996).
51. Eisenhauer EA, Vermorken JB. The taxoids: comparative clinical pharmacology and therapeutic potential. Drugs 55(1), 5-30 (1998).
52. Taron M, Plasencia C, Abad A, Martin C, Guillot M. Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines. Invest. New Drugs 18(2), 139-147 (2000).
53. Ferlini C, Scambia G, Distefano M et al. Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis. Br. J. Cancer 75(6), 884-891 (1997).
54. Chou TC, Otter GM, Sirotnak FM. Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. Cancer Chemother. Pharmacol. 37(3), 222-228 (1996).
55. Hübner B, Eckert K, Maurer HR. Synergistic and antagonistic interactions between docetaxel and interferon-β on growth of human breast cancer cells in vitro. Int. J. Oncol. 9, 625-628 (1996).
56. Hahm HA, Dunn VR, Butash KA et al. Combination of standard cytotoxic agents with polyamine analogues in the treatment of breast cancer cell lines. Clin. Cancer Res. 7(2), 391-399 (2001).
57. Pegram MD, Konecny GE, O'Callaghan C et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl Cancer Inst. 96(10), 739-49 (2004).
58. Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin. Cancer Res. 10(12 Pt 2), S4270-S4275 (2004).
59. Inoue K, Chikazawa M, Fukata S et al. Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM- 1470) in metastatic human transitional cell carcinoma. Clin. Cancer Res. 9(2), 886-899 (2003).
60. Zeng S, Chen YZ, Fu L, Johnson KR, Fan W. In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells. Clin. Cancer Res. 6(9), 3766-3773 (2000).
61. Dykes DJ, Bissery MC, Harrison JSD et al. Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere). Invest. New Drugs 13(1), 1-11 (1995).
62. Bissery MC, Couteau C, Oulid-Aïssa D. Docetaxel in combination with irinotecan: prediction of clinical maximum tolerated dose. Proc. Am. Soc. Clin. Oncol. 16, 221 (1997).
63. Sawada N, Ishikawa T, Fukase Y Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin. Cancer Res. 4(4), 1013-1019 (1998).
64. Eckardt JR. Antitumor activity of docetaxel. Am. J. Health Syst. Pharm. 54(24 Suppl. 2), S2-S6 (1997).
65. Riou JF, Naudin A, Lavelle F. Effects of taxotere on murine and human tumor cell lines. Biochem. Biophys. Res. Comm. 187(1), 164-170 (1992).
66. Vanhoefer U, Cao S, Harstrick A et al. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multi-drug resistance protein (MRP). Ann. Oncol. 8(12), 1221-1228 (1997).
67. Valero V, Jones SE, Von Hoff DD et al. A Phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin. Oncol. 16(10), 3362-3368 (1998).
68. Fossella FV, DeVore R, Kerr RN et al. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol. 18 (12), 2354-2362 (2000); Erratum in: J. Clin. Oncol. 22(1), 209 (2004).
69. Chang JC, Wooten EC, Tsimelzon A et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J. Clin. Oncol. 23(6), 1169-1177 (2005).
70. Iwao-Koizumi K, Matoba R, Ueno N et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J. Clin. Oncol. 23(3), 422-431 (2005).
71. Nabholtz JM. Docetaxel-anthracyclines combinations in metastatic breast cancer. Breast Cancer Res. Treat. 79(1), 3-9 (2003).
72. 2 in patients with metastatic breast cancer according to die status of anthracycline resistance. J. Clin. Oncol. 19(2), 336-342 (2001).
73. 2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy - a Phase II single-center study. J. Clin. Oncol. 17(4), 1127-1131 (1999).
74. Trudeau ME. Docetaxel (Taxotere): an overview of first-line monotherapy. Semin. Oncol. 22(6 Suppl. 13), 17-21 (1995).
75. 2 as second-line chemotherapy in advanced breast cancer. Br Cancer Res. Treat 81, 327a (2002).
76. Brodowicz T, Koestler WJ, Tomek S et al. Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer. Anticancer Drugs 11(3), 149-153 (2000).
77. Ferraresi V, Milella M, Vaccaro A et al. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a Phase II study. Am. J. Clin. Oncol. 23(2), 132-139 (2000).
78. Burstein HJ, Manola J, Younger J et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J. Clin. Oncol. 18(6), 1212-1219 (2000).
79. Stemmler HJ, Gutschow K, Sommer H et al. Weekly docetaxel (Taxotere®) in patients with metastatic breast cancer. Ann. Oncol. 12(10), 1393-1398 (2001).
80. Stemmler J, Mair W, Stauch M et al. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer. Oncology 68(1), 71-78 (2005).
81. Hainsworth JD, Burris III HA, Yardley DA et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network Phase II trial. J. Clin. Oncol. 1905), 3500-3505 (2001).
82. Tabernero J, Climent MA, Lluch A et al. A multicentre, randomised Phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann. Oncol. 15(9), 1358-1365 (2004).
83. Nabholtz JM, Senn HJ, Bezwoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J. Clin. Oncol. 17(5), 1413-1424 (1999).
84. Sjostrom J, Blomqvist C, Mouridsen H et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised Phase III study with crossover on progression by the Scandinavian Breast Group. Eur. J. Cancer. 35(8), 1194-1201 (1999).
85. Bonneterre J, Roche H, Monnier A et al. Docetaxel vs. 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br. J. Cancer 87(11), 1210-1215 (2002).
86. Chan S, Friedrichs K, Noel D et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. 17(8), 2341-2354 (1999).
87. Ravdin P, Erban J, Overmoyer B et al. Phase III comparison of docetaxel (D) and paclitaxel (P) in patients with metastatic breast cancer (MBC). Eur. J. Cancer Suppl. S201, 670a (2003).
88. Misset JL, Dieras V, Gruia G et al. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann. Oncol. 10, 553-560 (1999).
89. Nabholtz JM, Mackey JR, Smylie M et al. Phase II Study of docetaxel,doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J. Clin. Oncol. 19(2), 314-321(2001).
90. Sparano JA, O'Neill A, Schaefer PL, Falkson CI, Wood WC. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Co-operative Oncology Group Study E1196. J. Clin. Oncol. 18(12), 2369-2377 (2000).
91. Pagani O, Sessa C, Nole F et al. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicenter Phase I-II study. Ann. Oncol 11 (8), 985-991 (2000).
92. Mavroudis D, Alexopoulos A, Ziras N et al. Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter Phase II study. Ann. Oncol. 11(10), 1249-1254 (2000).
93. Viens P, Roche H, Kerbrat P et al. Epirubicin-docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study. Am. J. Clin. Oncol. 24(4), 328-335 (2001).
94. Nabholtz JM, Falkson C, Campos D et al. Docetaxel and doxorubicin (AT) compared to doxorubicin and cyclophosphamide (AC) as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, Phase III trial. J. Clin. Oncol. 21(6), 968-975 (2003).
95. Nabholtz JM, Paterson A, Dirix L et al. A Phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 20, 22a (2001).
96. Mackey JR, Paterson A, Dirix LY et al. Final results of the Phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 21, 35a (2002).
97. Bontenbal M, Braun JJ, Creemers GJ et al. Phase III study comparing AT (adriamycin, docetaxel) to FAC (fluorouracil, adriamycin, cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC). Eur. J. Cancer 1, S201 (2003).
98. Bonneterre J, Dieras V, Tubiana-Hulin M et al. Phase II multicentre randomised study of docetaxel plus epirubicin vs. 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br. J. Cancer 91(8), 1466-1471 (2004).
99. Nabholtz JM, Cantin J, Chang J et al. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial. Clin. Breast Cancer 3(4), 268-275 (2002).
100. Spielmann M, Tubiana-Hulin M, Namer M et al. Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised Phase II trial. Br. J. Cancer 86(5), 692-697 (2002).
101. Perez EA, Geeraerts L, Suman VJ et al. A randomized Phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. Ann. Oncol. 13(8), 1225-1235 (2002).
102. Paridaens R, Van Aelst F, Georgoulias V et al. A randomized Phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer. Ann. Oncol. 14(3), 433-440 (2003).
103. Alba E, Martin M, Ramos M et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) Phase III study. J. Clin. Oncol. 22(13), 2587-2593 (2004).
104. Cresta S, Grasselli G, Mansutti M et al. A randomized Phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. Ann. Oncol. 15(3), 433-439 (2004).
105. Bria E, Giannarelli D, Felici IA et al. Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma. Cancer 103(4), 672-679 (2005).
106. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin. Cancer Res. 4(4), 1013-9 (1998).
107. Tonkin K, Scarfe A, Koski S et al. Preliminary results of a Phase I/II study of weekly docetaxel (Taxotere) combined with intermittent capecitabine (Xeloda) for patients with anthracycline pre-treated metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 20, 67b (2001).
108. Meza LA, Amin B, Horsey M et al. A Phase II study of capecitabine in combination with paclitaxel as first or second line therapy in patients with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 20, 70b (2001).
109. Venturini M, Del Mastro L, Merlano M et al. Dose-finding study of capecitabine in combination with docetaxel and epirubicin in prior untreated advanced breast cancer patients. Proc. Am. Soc. Clin. Oncol. 19, 108a, Abstract 419 (2000).
110. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J. Clin. Oncol. 20(12), 2812-2823 (2002).
111. Kornek GV, Ulrich-Pur H, Penz M et al. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J. Clin. Oncol. 190), 621-627 (2001).
112. Marti JL, Bueso P, Mayordomo JI et al. Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines. Ann. Oncol. 12(8), 1061-1065 (2001).
113. Rodriguez J, Calvo E, Cortes J et al. Docetaxel plus vinorelbine as salvage chemotherapy in advanced breast cancer: a Phase II study. Breast Cancer Res. Treat. 76(1), 47-56 (2002).
114. Airoldi M, Cattel L, Pedani F et al. Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/relapsed metastatic breast cancer. Acta Oncol. 42(3), 186-194 (2003).
115. Vassilomanolakis M, Koumakis G, Drufakou S et al. Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer. Cancer Chemother. Pharmacol. 51(2), 179-183 (2003).
116. Cals L, Nouyrigat P, Valenza B, Pedinelli FJ, Juin P. Weekly combination of docetaxel and vinorelbine in metastatic breast cancer: a Phase VII study. Oncology 67(3-4), 257-261 (2004).
117. Mayordomo JI, Milla A, Morales S et al. Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer. Clin. Breast Cancer 5 (2), 131-135 (2004).
118. Gomez-Bernal A, Cruz JJ, Olaverri A et al. Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer. Anticancer Drugs 16(1), 77-82 (2005).
119. Spiridonidis CH, Laufman LR, Jones J, Rhodes VA, Wallace K, Nicol S. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. J. Clin. Oncol. 16(12), 3866-3873 (1998).
120. Rischin D, Boyer M, Smith J et al. A Phase I trial of docetaxel and gemcitabine in patients with advanced cancer. Ann. Oncol. 11(4), 421-426 (2000).
121. Laufman L, Spiridonidis C, Pritchard J et al. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a Phase II trial. Ann. Oncol. 12(9), 1259-1264 (2001).
122. Palmeri S, Vaglica M, Accurso V et al. Weekly docetaxel (doc) and gemcitabine (gem) as first line therapy for advanced breast cancer (ABC): a multicenter Phase II trial. Proc. Am. Soc. Clin. Oncol. 21, 45b, Abstract 1991 (2002)
123. Fountzilas G, Nikolaides C, Bafaloukos D et al. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Co-operative Oncology Group Phase II study. Cancer Invest. 18(6), 503-509 (2000).
124. Mavroudis D, Malamos N, Polyzos A et al. Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter Phase II study. Oncology 67(3-4), 250-256 (2004).
125. Brandi M, Vici P, Lopez M et al. Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter Phase II study. Semin. Oncol. 31(2 Suppl. 5), 13-19 (2004).
126. Kornek GV, Haider K, Kwasny W et al. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clin. Cancer Res. 8(5), 1051-1056 (2002).
127. Pelegri A, Calvo L, Mayordomo JI et al. Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: preliminary results from a Phase II trial. Semin. Oncol. 31(2 Suppl. 5), 20-24 (2004).
128. Crown JP. The platinum agents: a role in breast cancer treatment? Semin. Oncol. 28 (1 Suppl. 3), 28-37 (2001).
129. Spielmann M, Llombart A, Zelek L, Sverdlin R, Rixe O, Le Cesne A. Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer. Ann. Oncol. 10(12), 1457-1460 (1999).
130. Mavroudis D, Alexopoulos A, Malamos N et al. Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter Phase II trial. Oncology. 64(3), 207-212 (2003).
131. Vassilomanolakis M, Koumakis G, Barbounis V et al. First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer. Breast 14(2), 136-141 (2005).
132. Slamon D, Godolphin W, Jones LA et al. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712 (1989).
133. Nabholtz J-M, Pienkowski T, Northfelt D et al. Results of two open-label multicentre Phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (cis or carboplatin) (TCH) as therapy for advanced breast cancer (ABC) in women with tumors overexpressing the HER2-neu proto-oncogene. Eur. J. Cancer 37(Suppl. 6), 695a (2001).
134. Hurley JE, Doliny P, Velez P et al. High rate of axillary node clearance with neoadjuvant Herceptin, Taxotere, and cisplatin in locally advanced and inflammatory breast cancer. Breast Cancer Treat. Res. 69, 516a (2001).
135. Nabholtz JM, Pienkowski T, Mackey J et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node-positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc. Am. Soc. Clin. Oncol. 21, 141a (2002).
136. Martin M, Pienkowski T, Mackey J et al. TAC improves disease Free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. Breast Cancer Res. Treat. 82, 43a (2003).
137. Roche H, Fumoleau P, Spielmann M et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC 100 vs. 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. Breast Cancer Res. Treat. 83, 27a (2004).
138. Wolmark N, Wang J, Mamounas E et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J. Natl. Cancer Inst. Monogr. 30, 96-102 (2001).
139. Bear HD, Anderson S, Smith RE et al. A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: results of NSABP B-27. Breast Cancer Res. Treat. 88(Suppl. 1), 26a (2004).
140. Jackisch C, von Minckwitz G, Eidtmann H et al. Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis. Clin. Breast Cancer 3(4), 276-280 (2002).
141. Smith IC, Heys SD, Hutcheon AW et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J. Clin. Oncol. 20, 1456-1466 (2002).